Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches

Remón, Jordi; Pardo, Núria; Martinez-Martí, Alex; Cedrés, S.; Navarro, Alejandro; Castro, Ana; Felip, Enriqueta

doi:10.1016/j.lungcan.2017.02.002

Cited by 29 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Balb/c mice injected with A549 or H1299 cells treated with 300 mg/kg/day metformin in combination with 10 Gy ionizing radiation (IR) until euthanasia showed inhibition of xenograft growth, activation of the AMPK-p53 pathway, inhibition of the mTOR-4EBP1 pathway, reduced angiogenesis and enhanced expression of apoptotic markers [69]. Compromised immune system responses play an important role in cancer and in recent years immune related therapies have been developed and shown to have strong clinical benefits [72,73,74]. Some of metformin’s anti-cancer effects have been proposed to be immune-mediated [75,76].…”

Section: Effects Of Metformin In Lung Cancer: In Vivo Studiesmentioning

confidence: 99%

Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies

Yousef

Tsiani

2017

Cancers

View full text Add to dashboard Cite

Cancer cells display enhanced growth rates and a resistance to apoptosis. The ability of cancer cells to evade homeostasis and proliferate uncontrollably while avoiding programmed cell death/apoptosis is acquired through mutations to key signaling molecules, which regulate pathways involved in cell proliferation and survival and these mutations allow them to develop resistance to many chemotherapeutic agents, highlighting the need for development of new potent anti-cancer agents. Metformin has long been used as a treatment for type 2 diabetes and has recently attracted attention as a potential agent to be used in the treatment of cancer. The present review summarizes the existing in vitro and in vivo animal studies focusing on the anti-lung cancer effects of metformin and its effects on key proliferative and anti-apoptotic signaling pathways.

show abstract

Section: Effects Of Metformin In Lung Cancer: In Vivo Studiesmentioning

confidence: 99%

Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies

Yousef

Tsiani

2017

Cancers

View full text Add to dashboard Cite

show abstract

“…USA FDA gave approval to nivolumab as a treatment for metastasis NSCLC squamous patients with development on or after platinum-based chemotherapy in 2015. 1,6 In CheckMate 057 study, the nivolumab response rate compared to docetaxel was 19% versus 12% (p = 0.02). Based on the data, FDA approved nivolumab for the treatment of NSCLC metastatic patients with a progressive response on or after recent platinum-based chemotherapy.…”

Section: Immune Checkpoint Inhibitor Developmentmentioning

confidence: 99%

“…The response rate with NSCLC squamous (16.7 %) and NSCLC non-squamous (17.6%). 1,6 NSCLC squamous phase II trials, the response rate in patients with PD-L1 tumor expression <5% was 14%, while in patients with PD-L1 expression ≥ 5% is 24%. Phase III trials were performed on 272 NSCLC squamous patients who developed disease during or after first-line chemotherapy.…”

Section: Immune Checkpoint Inhibitor Developmentmentioning

confidence: 99%

“…This agreement extends the indication of nivolumab in NSCLC to include non-squamous histology. 1,6 Research studies are conducted to evaluate the efficacy and safety of nivolumab monotherapy in patients with NSCLC who have recently undergone chemotherapy. The objective response was 31% (8/26) in PD-L1 positive patients and 10% (2/21) in PD-L1.1 negative patients.…”

Section: Immune Checkpoint Inhibitor Developmentmentioning

confidence: 99%

“…A new therapeutic approach works by stimulating an anti-cancer immune response so that the development of lung cancer cells can be prevented. [5][6][7] Lung Cancer Immunology Lung cancer is lung tissue that proliferates uncontrollably. Genetic changes in cancer can be in the forms of mutations that cause an increase in protoonco-genic function and mutations that cause loss of tumor suppressor gene function.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immune-checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Hariyati¹,

Mayasari

2020

View full text Add to dashboard Cite

Lung cancer is the primary cause of mortality in the world. It is able to manipulate the host immune response system through many mechanisms, such as through alteration of cytokines structure, forming regulator T-cells, obstruction of cellular immunity function, and the interference of tumor antigen presenting process. The new therapy approachment is produced by stimulating anti-cancer immune response, therefore the growth of lung cancer is able to inhibit. Immune checkpoint inhibition is considered as therapy for non-small cell lung carcinoma (NSCLC) after the unsuccessful treatment by platinum-based chemotherapy. Recent study shows that immune checkpoint inhibition monotherapy is more distinguished as first line therapy than platinum-based chemotherapy. Nonetheless, the effect of immunotherapy is only available for small population (30%) which has more than 50% PD-L1 programmed by the tumor. Therefore, some strategies are investigated to solve this issue. Nowadays, immunotherapy is expected to overcome lung cancer which is still being investigated in many studies.

show abstract